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Abstract
Background: Prior economic evaluations of adult and adolescent vaccination strategies against pertussis have reached
disparate conclusions. Using static approaches only, previous studies failed to analytically include the indirect benefits
derived from herd immunity as well as the impact of vaccination on the evolution of disease incidence over time.
Methods: We assessed the impact of different pertussis vaccination strategies using a dynamic compartmental model able
to consider pertussis transmission. We then combined the results with economic data to estimate the relative cost-
effectiveness of pertussis immunization strategies for adolescents and adults in the US. The analysis compares combinations
of programs targeting adolescents, parents of newborns (i.e. cocoon strategy), or adults of various ages.
Results: In the absence of adolescent or adult vaccination, pertussis incidence among adults is predicted to more than
double in 20 years. Implementing an adult program in addition to childhood and adolescent vaccination either based on 1)
a cocoon strategy and a single booster dose or 2) a decennial routine vaccination would maintain a low level of pertussis
incidence in the long run for all age groups (respectively 30 and 20 cases per 100,000 person years). These strategies would
also result in significant reductions of pertussis costs (between 277% and 280% including additional vaccination costs).
The cocoon strategy complemented by a single booster dose is the most cost-effective one, whereas the decennial adult
vaccination is slightly more effective in the long run.
Conclusions: By providing a high level of disease control, the implementation of an adult vaccination program against
pertussis appears to be highly cost-effective and often cost-saving.
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Introduction
Pertussis vaccines were first licensed in the United States (US) in
1914 and were combined with diphtheria and tetanus toxoids in
1918 [1]. Their widespread use in the 1940s for infant vaccination
led to a dramatic reduction in pertussis (whooping cough) cases. In
1976, the number of reported cases in the US hit an all-time low of
just over 1,000 [2]. The incidence of reported pertussis has
thereafter steadily increased over the past two decades, with an
increasing proportion of cases reported among adolescents and
adults [3–6]; this resurgence means that pertussis is again a public
health concern. In 2004, the Centres for Disease Control and
Prevention (CDC) reported 25,827 cases of pertussis, representing
an incidence of 8.9 per 100,000 US population [5]. Due to a lack
of clinical awareness, insensitivity of culture and polymerase-
chain-reaction (PCR) techniques, and a lack of standardized
serological testing and criteria, the reported incidence is estimated
to represent only a fraction of the true incidence [7–9].
Furthermore, under-diagnosis may occur differentially according
to age, with most adult cases not being detected or reported. This is
illustrated by data from the Acellular Pertussis Vaccine Trial
(APERT), which reported an incidence of 370 to 450 cases per
100,000 person years in adolescents and adults [10], compared to
the reported US incidence of 1.1 and 7.7 per 100,000 adults (aged
$20 years) and adolescents (aged10 to 19 years), respectively [5]. In
addition, the APERT study found that there may be approximately
five cases of asymptomatic pertussis infection for every case of
symptomatic infection in adults and adolescents, which may
contribute to the circulation of Bordetella pertussis in the community
[11]. These data suggests that there may be as many as 700,000 to
8,000,000 cases of pertussis, either symptomatic or asymptomatic,
in any given year in the adult and adolescent population as a whole.
In view of the clear burden of pertussis among older age groups,
and to reduce transmission of B. pertussis in health care settings and
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Committee on Immunization Practices (ACIP) has issued
recommendations for routine adolescent booster vaccination
[15], and routine or targeted vaccination of adults [16]. In
addition, the ACIP has recently reaffirmed its recommendation for
the use of TdaP in post-partum women to help to protect the
newborn [17].
Determining the optimal adult vaccination strategy requires an
assessment of both the economic and epidemiologic impact of
alternative strategies. A recent review discussed an economic
analysis of adolescent and adult pertussis vaccination [18]. Among
the US-specific studies, no consensus has been reached on their
economic value since different studies led to inconsistent results
[19–22]. One cost-benefit analysis has shown that routine
vaccination in both adolescents and adults provides significant
health benefits and are cost savings [22] while another economic
analysis concludes that routine pertussis vaccination is likely to be
cost-effective for adolescents but not for adults [20]. More
recently, an economic evaluation concludes that adult pertussis
vaccination is cost-effective if the disease incidence in adults is
greater than 120 cases per 100,000 population [21]. Despite these
discrepancies, all these studies have consistently shown that the
level of incidence and the potential herd immunity effects are key
drivers of the results [19,22,23]. Paradoxically, all these studies fail
to properly consider these two factors. Firstly, communicable
diseases are more appropriately modeled using dynamic models
that are able to directly take into account the transmission of the
disease in the population [24]. None of the previous studies used
that approach; at best they used a potential reduction of incidence
for unvaccinated individuals in their sensitivity analyses. Second, it
can be hypothesized that the recent resurgence of pertussis is
symptomatic of a waning of the population immunity coupled with
particular transmission dynamics between age groups. Thus, a
recent analysis [25], published by some of the authors of the
present study, uses an epidemiological model initially developed by
Hethcote [26] to analyze the potential impact of adult vaccination
in the US. In particular, this study shows how the progressive shift
from ‘‘naturally acquired immunity’’ to ‘‘vaccine-acquired immu-
nity’’ triggers large fluctuations in disease incidence for some
vaccination strategies; but the economic consequences of such
fluctuations were overlooked.
In the present study, we aim to fill that gap by combining the
results of this epidemiological model with cost data to estimate the
relative cost-effectiveness of new adult vaccination strategies.
Methods
Epidemiological model
The cost-effectiveness analysis builds upon on a compartmental
age-structured transmission model of pertussis in the US [25],
which is an update of previous published transmission models of
pertussis [26–28]. In brief, the model stratifies the US population
in 50 age groups and compartmentalizes them into three main
pertussis states: fully susceptible, fully or partially immune, and
infectious. The infectious state is split into typical, mild and
asymptomatic, each having its own duration and level of
infectiousness. There are four vaccination compartments depend-
ing on the number of doses received. A difference is made between
vaccine-acquired and natural immunity, both of which wane over
time in three different phases (Table 1). The median duration of
residence in each phase is 4 years for vaccine immunity waning
and 8 years for natural immunity waning. Transfers between states
occur because of vaccination and exposure to B. pertussis. The
distribution of outcomes in the event of exposure depending on
immunological status is given in Table 1. The rates of outcome do
not differ from the distribution published by Coudeville et al. [25].
Rates of exposure (or infection) are ‘‘dynamic’’ and determined by
the proportion of individuals in the various states and the related
forces of infection.
Age-specific forces of infection for symptomatic disease were
calculated during the calibration process to match the observed
incidence. For adolescents and adults, the force of infection was
based on incidence data reported in APERT [10,22]. For children,
CDC surveillance data [5] were adjusted for under-reporting using
age-specific under-reporting estimates [7]. To address the
potential infectiousness of asymptomatic disease, data from a
recent study suggesting that 16% of infections in infants are the
result of transmission of asymptomatic disease were used to
calibrate the model [29]. The age-specific forces of infection were
identified using a ‘who acquires infection from whom’ (WAIFW)
matrix whose structure had been used in previous publications
[25,27,30].
Estimates for efficacy of the primary series vaccination in
children were based on a recent case-control study of pertussis
vaccination in children aged 6 to 59 months in the US [31].
Depending on the number of doses administered (one to four), the
initial protection is estimated to range from 46.0% to 96.4%. For
adolescents and adults, we used the 92% vaccine efficacy observed
in the APERT trial [10].
Finally, sources of infection for infants were calculated from
published data [29,32] and are presented in Table 2, along with
other key parameters used in the epidemiological model.
Vaccination strategies
Health economic outcomes were evaluated for the following
vaccination scenarios: (1) primary series vaccination in children
(Childhood vaccination); (2) primary childhood series vaccination plus
routine adolescent vaccination at 12 years of age (childhood+adoles-
cent); (3) primary childhood series vaccination, routine adolescent
vaccination, plus targeted vaccination of parents of newborns (i.e.,
cocoon vaccination) starting at 20 years of age (Childhood+adoles-
Table 1. Distribution of outcomes in case of exposure.
Type of infection
Compartments Typical Mild Asymptomatic
Susceptible 73% (73–73) 25% (25–25) 2% (2–2)
Immune 0% (0–0) 0% (0–0) 0% (0–0)
Natural waning 1 10% (10–10) 30% (41–41) 45% (45–45)
Natural waning 2 5% (5–5) 15% (15–15) 35% (35–35)
Natural waning 3 0% (0–0) 10% (10–10) 30% (30–30)
Vaccine 1 7% (0–73) 38% (2–25) 34% (12–2)
Vaccine 2 1% (0–23) 14% (2–51) 30% (12–20)
Vaccine 3 0% (0–2) 7% (2–22) 23% (12–34)
Vaccine 4 0% (0–0) 2% (0–11) 12% (4–27)
Vaccine waning 1 49% (9–73) 42% (42–25) 8% (31–2)
Vaccine waning 2 5% (1–34) 34% (15–49) 35% (31–14)
Vaccine waning 3 0% (0–2) 7% (2–22) 23% (12–34)
Distribution of outcomes in case of contact with an infectious person according
to immunological status. Values for susceptible, immune and natural waning
are taken from Van Rie et al.[25]. Values for vaccine-related compartments are
estimated using Bisgard et al.[31]a n dWard et al. [10]. Figures in parentheses
define the range used in the sensitivity analysis.
doi:10.1371/journal.pone.0006284.t001
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adolescent vaccination, targeted vaccination of parents of
newborns, plus a single dose of vaccine for adults as per the
ACIP recommendation of December 2006 (Childhood+adolescent+1
dose at 40 years); and (5) primary childhood series vaccination,
routine adolescent vaccination, plus routine vaccination of adults
every 10 years (childhood+adolescent+routine adult). The base case
analyses assumed 80% to 96% coverage depending on age in
infants and children, 75% in adolescents, 40% with routine adult
vaccination, and 65% in parents of newborns [25]. We varied the
coverage rate of the two latter strategies in sensitivity analysis using
respectively the ranges [20%–60%] and [35%–95%].
Cost Inputs
For children and adolescents, CDC surveillance data corrected
for under-reporting were used to estimate the incidence of
pertussis cases requiring medical attention. We assumed that all
symptomatic infections in children and adolescents led to some
medical care. For adults (20 years and above), the gap between the
estimates of the incidence derived from the APERT trial and CDC
surveillance corrected for under-reporting [25] led to an estimate
that only 48.7% of typical cases and 0% of mild cases receive some
form of medical care. Using this approach we estimated that the
incidence of adult cases requiring medical attention was 90 per
100,000 individuals in 2004 (ranging in sensitivity analyses from
44 to 165).
For cases requiring medical care, age-specific costs for mild and
typical pertussis cases were calculated based on published
estimates [20,33,34] updated to 2006 levels using the US price
index for medical care (available at www.bls.gov). Estimates
include both direct and indirect costs, and are categorized into
short-term costs and costs resulting from long-term disability or
pertussis-related death (Table 3). Short-term direct costs stand for
medical costs for mild or severe cough and/or pneumonia
including physician visits, emergency room visits, hospitalization,
chest radiographies, laboratory tests, and use of antibiotics and
other drugs. Those outcomes are weighted by their rate of
occurrence in the different age groups (i.e. ,1 year, 1–9 years, 10–
17 years, $18 years). Long-term direct medical care costs include
the medical costs for disabilities and apply only to patients with
long-term sequelae following infection. Short-term indirect costs
include the costs for reduced work productivity and absence from
work occurring during the pertussis episode. Time lost from non-
work activities was not included. In addition we took into account
the long-term indirect costs related to lost productivity from death
and permanent disabilities. We assumed that mild cases never
result in severe outcomes (i.e. death, permanent disability, or
hospitalization).
Vaccination costs included in these analyses are those associated
with vaccination of adolescents and adults only, as childhood
vaccination is a component of all of the simulated strategies. For
the cost of the vaccine itself, we applied the price difference
between a combined Td vaccine and the price of a combined
TdaP vaccine in the public sector ($14.13 available at http://
www.cdc.gov/nip/vfc/cdc_vac_price_list.htm, March 01, 2007),
as routine administration of Td vaccine is a long-standing
recommendation in the US. For the same reason, we did not
apply additional administration costs associated with routine
vaccination of adolescent and adults. For the cocoon strategy,
we assumed that an additional medical visit would be needed for
fathers of newborns but not for mothers. These additional visits
were valued at $30. Adverse events were assumed to lead to an
additional medical consultation in 2% of vaccinees, or 0.74$ per
vaccine dose administered [20].
Table 2. Key parameters in the epidemiological model.
Parameter
Estimate [Range in Sensitivity
Analyses]
Duration of infectiousness
[23]
Typical case 4 weeks
Mild case 3 weeks
Asymptomatic case 1 week
Vaccine efficacy[
10,26]
After the first dose 46.0% [0.0–88.2]
After the second dose 79.6% [24.6–94.5]
After the third dose 91.7% [74.5–97.3]
After the fourth dose 96.4% [86.4–99.0]
After booster dose 92.0% [32.0–99.0]
Vaccine coverage
Childhood Between 80% & 96% depending on
age
Adolescent 75%
Cocoon strategy 65% [35%–95%]
Routine adult vaccination 40% [20%–60%]
% of cases resulting from exposure to household contacts
[27,28]
0–1 months 48.1% [38.0, 58.2]
2–3 months 48.1% [38.0, 58.2]
4–5 months 48.1% [38.0, 58.2]
6–12 months 33.6% [25.6–41.6]
13–18 months 39.2% [25.5, 52.9]
19–24 months 41.7% [25.0, 58.3]
2 years 38.2% [23.5, 55.9]
3 years 41.5% [26.8, 56.1]
4 years 40.5% [26.2, 54.8]
5 years 23.6% [12.7, 34.5]
Case fatality rates
[29]
Typical cases
,1 year 0.69% [0.52–0.86]
1–9 years 0.05% [0.04–0.06]
10–17 years 0% [0–0]
18+ years 0.03% [0.02–0.04]
Mild cases
,1 year 0.0% [0–0]
1–9 years 0.0% [0–0]
10–17 years 0.0% [0–0]
18+ years 0.0% [0–0]
Rates of long term sequelae
[29]
Typical cases
,1 year 0.06% [0.05–0.08]
1–9 years 0.02% [0.01–0.02]
10–17 years 0.02% [0.01–0.02]
18+ years 0.02% [0.01–0.02]
Mild cases
,1 year 0.0% [0–0]
1–9 years 0.0% [0–0]
10–17 years 0.0% [0–0]
18+ years 0.0% [0–0]
doi:10.1371/journal.pone.0006284.t002
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Because the direct and indirect impact of the implementation of
new vaccination strategies is not instantaneous, health and
economic outcomes were examined over time, with the initiation
date set as the beginning of 2006. Results are given at steady-state
(when the full impact of vaccination has been reached) but also
with a specific time horizon of 100 years. Costs are measured for a
cohort of one million individuals. Net societal costs were used as
the numerator, and discounted life years gained (LYG) as the
denominator. All costs and outcomes are discounted at 3% per
annum ranging from 0% to 5% in sensitivity analyses. Although
not formally justified in the literature, we applied the widely used
threshold of $100,000/LYG to consider a strategy as being cost-
effective since several publicly funded interventions have been
estimated around that threshold. A strategy is identified as
dominating its comparator if both less expensive and more
effective (i.e. under $100,000/LYG) than any other strategy, and
as being dominated if both more expensive and less effective than
its comparator [35].
Sensitivity analyses were performed to identify the influence on
cost-effectiveness estimates of changes in key model parameters,
including vaccine efficacy, vaccine coverage, sources of transmis-
sion to young infants, case fatality rates, rates of long-term
sequelae and cost estimates. Ranges of values used in the sensitivity
analyses are presented in Tables 2 and 3.
Results
The epidemiological model predicts that adding a booster dose
of pertussis vaccine for adolescents to the current US childhood
vaccine schedule has a dramatic impact on the overall incidence of
pertussis, with a reduction in the overall incidence of symptomatic
pertussis from about 400 to less than 90 per 100,000 person years.
These gains, however, partially fade away in the long run. As the
average age of infection increases and immunity in adolescents
wanes, the overall pertussis incidence oscillates and reaches a new
steady-state of approximately 450 per 100,000 person years by
2060. The addition to adolescent and childhood immunization of
a selective vaccination targeting the parents of newborns (i.e.
cocoon strategy) would mitigate this increase and lead to a steady
state of 320 cases of symptomatic pertussis per 100,000 person
years. The two other adult strategies are able to achieve and
maintain a low level of pertussis incidence when combined with
childhood and adolescent programs: routine decennial adult
immunization and the combination of the cocoon strategy with
a single booster dose for all adults at 40 years of age (30 cases per
100,000 person years).
The impact of the different vaccination strategies on total
pertussis costs over time is shown in Figure 1. The evolution of
pertussis costs over time closely matches the evolution of pertussis
incidence. This stems from the fact that for the different strategies
considered, associated savings in pertussis treatment costs exceed
additional vaccination costs. Among all new strategies, the one
including the cocoon strategy and a single dose for all adults is the
least expensive whatever timeframe is considered. The only other
strategy that results in similar costs is the one involving decennial
routine vaccination for adults. This is also illustrated by the results
presented Table 4. As compared to the current childhood
vaccination strategy, the savings in disease-related costs for the
strategy including adolescent, cocoon and a single adult booster
vaccination ($2,581,361) are 6 times the additional vaccination
costs ($499,132); 3.5 times if one only considers direct treatment
costs. In terms of cost-effectiveness results, the strategy including
one adult booster dose clearly dominates other strategies in the
base case. The only exception is the strategy including routine
decennial vaccination for adults but, while not being dominated at
steady-state, it is associated with a very high cost-effectiveness ratio
($678,523).
The age at which the single adult booster dose is administered
plays a key role in the value of this vaccination (Figure 2). When
one considers the steady-state situation (the full impact of adult
vaccination strategies) 40 years of age is the optimal age for this
booster dose both in terms of cost and effectiveness.
Sensitivity Analyses
The sensitivity analyses (Table 5) demonstrate vaccine efficacy
and disease incidence as the only factors to have a strong effect on
the cost-effectiveness results. Neither variation of vaccination
coverage, discount rate, costs, nor the extent of the cocoon effect
change the dominant strategy identified in the base case.
In the low vaccine efficacy scenario - i.e. lower bound of the
confidence interval derived from Bisgard et al.[31] and Ward et al.
[10] - implementing routine decennial vaccination appears, with a
ratio below $100,000, to be a more cost-effective solution than
Table 3. Estimates for the short term cost per case of pertussis infection (ranges used in sensitivity analyzes presented in
parentheses).
,1 year
+ 1–9 years
+ 10–17 years
# 18+ years
#
Typical cases
Short term direct costs $7,006 [5254–8757] $646 [484–807] $256 [192–320] $338 [254–423]
Short term indirect costs $390 [293–488] $390 [293–488] $174 [131–218] $501 [376–626]
Medical disability costs per year* $51,648 [38736–64560] $51,648 [38736–64560] $51,648 [38736–64560] $51,648 [38736–64560]
Indirect costs due to disability or
death per year**
$25,036 [18777–31295] $25,036 [18777–31295] $25,036 [18777–31295] $25,036 [18777–31295]
Mild cases
Short term direct costs $377 [283–472] $256 [192–320] $219 [164–274] $265 [198–331]
Short term indirect costs $390 [293–488] $390 [293–488] $174 [131–218] $501 [376–626]
*Applies only to the fraction of patients with long term sequelae following infection.
**Applies only to the fraction of patients with fatal cases of pertussis or long term sequelae following infection.
+Caro et al. [43] updated to 2006 using CPI for medical care (www.bls.gov).
#Lee et al. [20] updated to 2006 using CPI for medical care (www.bls.gov).
doi:10.1371/journal.pone.0006284.t003
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doi:10.1371/journal.pone.0006284.g001
Table 4. Cost-effectiveness results in the base case.
Childhood
vaccination
Childhood+
adolescent
Childhood+
adolescent+
cocoon
Childhood+
adolescent+
cocoon+1 dose at
40 yrs
Childhood+
adolescent+
routine adult
Costs/Year–
Steady state situation
$
Vaccination Cost* $0 $192,859 $385,840 $499,132 $623,950
Disease cost
-treatment related $1,184,025 $681,428 $455,238 $49,616 $37,524
-short-term indirect $1,140,057 $814,248 $575,076 $60,012 $41,029
-sequelae-related $611,767 $423,178 $288,640 $28,476 $20,528
-long-term indirect $296,551 $205,133 $139,917 $13,804 $9,951
Total costs $3,232,400 $2,316,846 $1,844,711 $651,040 $732,981
Outcomes/Year
$
Deaths 0.79 0.55 0.37 0.04 0.03
Sequelae 0.58 0.46 0.33 0.03 0.02
Life years lost 18.01 10.85 6.80 0.71 0.59
Cost per life year gained
{
Reference Dominating Dominating Dominating Dominating
Dominated Reference Dominating Dominating Dominating
Dominated Dominated Reference Dominating Dominating
Dominated Dominated Dominated Reference $682,842
*Cost for vaccinating adults and adolescents excluding those for doses given to children.
{Calculated by comparing each strategy to the one chosen as reference. A strategy is identified as dominating its comparator if both less expensive and more effective
(i.e. under $100,000/LYG) than any other strategy, and as dominated if both more expensive and less effective than its comparator. Cost per life year gained is shown
for a strategy more effective but more costly.
$Costs and outcomes are reported for 1,000,000 people, steady state situation corresponds to a period at which the full impact of the vaccination strategy considered
has been reached.
doi:10.1371/journal.pone.0006284.t004
Pertussis Control Strategies
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6284cocoon vaccination and a single booster dose at 40 years of age.
The situation is reversed for a high vaccine efficacy scenario:
implementing only the adolescent or adolescent and cocoon seems
to be sufficient and the cost-effectiveness ratio is higher than
$1,000,000 for the booster dose at 40 years of age.
A single booster dose at 40 years of age in addition to the
cocoon strategy remains the dominant strategy in the low
incidence scenario. The routine decennial vaccination for adults
becomes the dominant strategy for the high incidence scenario.
Discussion
This economic evaluation in the US is the first to build upon the
results of a pertussis transmission model to assess the economic
value of pertussis vaccination strategies. This kind of approach
takes into account some specific features of pertussis transmission.
For example, the progressive switch from naturally acquired
immunity to vaccine-acquired immunity is an essential character-
istic. It can trigger severe fluctuations in disease incidence which
impact the cost of strategies. This argument alone demonstrates
the relevance of considering disease dynamics when assessing the
economic value of a vaccination program. But, more importantly,
such as Beutels et al. [36] we do think that the capacity to prevent
individuals from infecting others should not be overlooked in the
assessment of the value of vaccines. This is of particular
importance for pertussis for which the age group with the highest
death rate (newborns) can only be protected indirectly.
Our results clearly highlight the epidemiologic and economic
value of adult pertussis vaccination when combined with a routine
childhood and adolescent schedule. Adult pertussis vaccination is
not only cost-effective but also cost-saving in most cases.
Combining a cocoon strategy targeting parents of newborns and
a single booster dose for all adults at 40 years of age appears to be
the most cost-effective solution over a wide range of scenarios.
Routine decennial vaccination is predicted to lead to only a slightly
higher level of costs and a slightly lower incidence, and is optimal
in the low vaccine efficacy or high incidence sensitivity analysis. If
one goes beyond strict economic criteria for evaluating strategies
and includes implementation issues, routine decennial vaccination
for adults may appear as the preferred strategy due to the existence
of a decennial Td program. Consequently, a simple replacement
of Td by TdaP would enable the anti-pertussis strategy to
capitalize on the current uptake of adult Td vaccination. As a
matter of fact, US data for 2007 published by CDC show that
57.2% of 18 to 65 years old [54%–60.5%, CI 95%] had received a
tetanus vaccine in the past 10 years [36]. For adolescents, more
than 72% had received either Td or TdaP [70%–74%] [36] since
the age of 10 years.
The fact that the age at which the adult booster dose is
administered modifies the economic value of a single adult booster
strategy is also worth mentioning. On this last point, it is important
to keep in mind that the results presented in Figure 2 correspond
to a steady-state situation (i.e. a period at which adolescent and
cocoon vaccination have been implemented for long enough to
reach their full impact). It is unclear whether similar findings
would be true over the short term.
Three other studies have evaluated the health economic
implications of adolescent and adult pertussis vaccination
strategies in the US [20–22]. Purdy et al. performed a cost-benefit
analysis and calculated the vaccine break-even cost for seven
different adolescent and adult immunization strategies. They
concluded that routine immunization of adolescents would be the
Figure 2. Variation in pertussis incidence and costs according to the age at which the adult booster dose is administered
(Childhood vaccination+adolescent+cocoon+1 booster dose for adult vaccination - steady-state situation).
doi:10.1371/journal.pone.0006284.g002
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every 10 years was also justified by their analysis, the authors
stated that the recommendation of routine adult vaccination
requires more certainty about key parameters including the
duration of immunity, program costs, compliance, and non-
medical costs associated with pertussis [22]. The authors did
recognize the limitation of excluding herd immunity in their
assessment, and acknowledged that including herd immunity may
increase the benefits of immunization.
A study by Lee at al [20] concluded that vaccination of adolescents
might be cost-effective, but that the addition of an adult vaccination
component was unlikely to be economically efficient. In a
subsequent analysis, more directly focused on adult immunization
[21], the same authors concluded that one-time and decennial
booster vaccination would be cost-effective if the disease incidence
in adults was greater than 120 cases per 100,000 population.
The analytic framework used in this analysis leads to different
conclusions. First, conditioning economic results to an incidence-
based threshold does not appear relevant if one considers the
predictions of our model. Using a threshold implicitly means that
the disease incidence is expected to remain stable if the vaccination
schedule is left unchanged. But our model predicts that in the
absence of any adolescent or adult program, pertussis incidence
will continue to increase especially amongst adults (90 per 100,000
person years in 2004, 231 in 2022). This prediction is consistent
with the trend observed by CDC surveillance over recent years [3–
5]. In this context, the main positive value of implementing an
adolescent and adult program is the ability to prevent the
resurgence of pertussis incidence in years to come.
The second major difference with Lee et al. study rests on the
treatment of herd immunity. Their analysis only included herd
immunity in sensitivity analyses but limited this to the effects of
vaccinating adults on the incidence of pertussis in infants. The
transmission model used in our analysis predicts that routine
decennial vaccination for adults would not only benefit adults and
infants but would also reduce pertussis incidence amongst children
and adolescents by more than 90% as compared to an
immunization schedule that only targets children and adolescents.
The rationale for using a dynamic epidemiologic model in these
analyses is to be able to capture both the direct and indirect
benefits of vaccination, as well as changes over time in the
epidemiology of pertussis expected following the implementation
of immunization programs. Economic evaluations conducted for
other infectious diseases have highlighted the importance of
including herd immunity. Recent examples include evaluations of
meningococcal disease [37] and hepatitis A [38]. In the latter case,
the inclusion of herd immunity effects more than doubled the
predicted savings over a 10 year period.
As with all models, our pertussis model is a simplified
description of the underlying processes that lead to disease and
of resource utilization. Furthermore, the selection of a specific
simulation technique, economic methods and parameter values is
essential but results in important limitations [39–41].
As is often the case in economic evaluations, we had to deal with
the uncertainty characterizing some of the key parameters of the
analysis. This uncertainty arose due to incomplete knowledge of
biological, demographic epidemiological, medical and economic
factors. The true incidence of infection across age groups in the
Table 5. Sensitivity analyzes on cost per discounted life year gained at steady state.
Childhood+adolescent Childhood+adolescent+cocoon
Childhood+adolescent+cocoon+1
dose at 40 yrs
Childhood+adolescent+routine
adult
Base case Dominated Dominated Dominating $678,523
Vaccine efficacy
High Reference $128,295 $1,190,068 Dominated
Low Dominated Dominated Dominating $95,962
Pertussis incidence
High Dominated Dominated Dominated Dominating
Low Dominated Dominated Dominating .$1,000,000
Vaccination coverage
High Dominated Dominated Dominating .$1,000,000
Low Dominated Dominated Dominating Dominated
Costs, case fatality & sequelae
High Dominated Dominated Dominating $471,812
Low Dominated Dominated Dominating .$1,000,000
Discount rate
0% Dominated Dominated Dominating $482,052
5% Dominated Dominated Dominating $837,402
Infection of infants and children via household contacts
High Dominated Dominated Dominating $999,924
Low Dominated Dominated Dominating $497,674
The cost per discounted life year gained is calculated by comparing each strategy with the strategy on its left. A strategy is identified as dominated if another one is
both more effective and less expensive, and as dominating if it is more effective and less costly than any other strategy or is always under the $100,000/LYG threshold.
In other cases, the cost effectiveness ratio is given taking as reference the dominating strategy or the one indicated as reference because none is dominating.
Optimal strategy in bold (i.e. dominating its comparator or with an ICER below $100,000/LYG).
doi:10.1371/journal.pone.0006284.t005
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on calibration of the model to data on incidence and under-
reporting of cases in the US, and uncertainty was addressed in
sensitivity analyses.
There are also limited data available on the costs associated with
mild, as opposed to typical, disease and there are no data on
unreported symptomatic infections, requiring us to rely in part on
assumptions (e.g., that mild disease would never lead to
hospitalization), and expert opinion [42]. We took a conservative
approach to assigning costs to cases of mild infection. We could
alternatively have considered that mild cases in specific popula-
tions, e.g. the elderly, also require medical attention specifically for
pertussis and/or as a trigger for another health event.
Mass vaccination can produce complex population effects that
make the type of model selected a critical factor [23]. To reduce
complexity, our model assumed a fixed vaccination schedule over
a 100 year period. The influence of immigration, possible
changing coverage rates over time, and potential changes in the
virulence of the B. pertussis organism, were also not evaluated.
Conclusions
Our simulation of the temporal evolution of pertussis epidemi-
ology and cost-effectiveness of vaccination strategies lends support
to pertussis adult vaccination strategies. In particular, our analysis
supports the hypothesis that the use of a pertussis vaccine in adults
in the US in addition to the childhood and adolescent program
could provide considerable health benefits and could be
economically viable. The vaccination strategy combining targeting
parents of newborns and a single booster dose for adults at 40
years of age appears to be the most cost-effective solution.
However, routine decennial vaccination would result in almost
similar costs and reduction of disease incidence. This last strategy
may be easier to implement since a decennial Td program is
already in existence.
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